Literature DB >> 7432437

Corticosteroid-treated chronic active hepatitis in remission: uncertain prognosis of chronic persistent hepatitis.

A J Czaja, J Ludwig, A H Baggenstoss, A Wolf.   

Abstract

To assess the prognosis of patients with severe chronic hepatitis after histologic examination had shown an improvement to chronic persistent hepatitis, we followed 52 such patients regularly for 54 +/- 4 months after the cessation of corticosteroid therapy. In 24 patients, the condition deteriorated 7 +/- 1 months after therapy and required further treatment with prednisone. Histologic features of chronic active hepatitis, including bridging and multilobular necrosis, were documented in all 14 patients in whom biopsies were performed. In 20 of 24 patients, the disease responded to retreatment, but 13 again had relapses, and cirrhosis developed in two. Of 28 patients who remained asymptomatic for 48 +/- 6 months, 17 retained features of chronic persistent hepatitis, and nine had improvement to normal histologic features. Cirrhosis developed in two patients without clinical manifestations of active inflammation. Findings before and after treatment did not predict outcome. We conclude that severe chronic active hepatitis that has been treated with prednisone and converted to chronic persistent hepatitis will often and unpredictably deteriorate after treatment has been stopped. Cirrhosis develops rarely but may occur with or without clinically overt chronic active hepatitis.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7432437     DOI: 10.1056/NEJM198101013040102

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  17 in total

Review 1.  Advances in the current treatment of autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2012-04-03       Impact factor: 3.199

2.  18F-FAC PET Selectively Images Liver-Infiltrating CD4 and CD8 T Cells in a Mouse Model of Autoimmune Hepatitis.

Authors:  Jessica R Salas; Bao Ying Chen; Alicia Wong; Donghui Cheng; John S Van Arnam; Owen N Witte; Peter M Clark
Journal:  J Nucl Med       Date:  2018-04-26       Impact factor: 10.057

Review 3.  Emerging opportunities for site-specific molecular and cellular interventions in autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2010-01-27       Impact factor: 3.199

Review 4.  Autoimmune Hepatitis: Surviving Crises of Doubt and Elimination.

Authors:  Albert J Czaja
Journal:  Clin Liver Dis (Hoboken)       Date:  2020-03-02

5.  Long-term observation of acute-onset autoimmune hepatitis presenting clinically and radiologically as acute hepatitis.

Authors:  Keiichi Fujiwara; Yoshihiro Fukuda; Katsushi Seza; Masaya Saito; Shin Yasui; Masayuki Nakano; Osamu Yokosuka; Naoya Kato
Journal:  Hepatol Int       Date:  2018-02-15       Impact factor: 6.047

6.  Remission of experimental autoimmune hepatitis is associated with antigen-specific and non-specific immunosuppression.

Authors:  A W Lohse; K H Meyer zum Büschenfelde
Journal:  Clin Exp Immunol       Date:  1993-10       Impact factor: 4.330

7.  Late relapse of type 1 autoimmune hepatitis after corticosteroid withdrawal.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2010-04-29       Impact factor: 3.199

Review 8.  Difficult treatment decisions in autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  World J Gastroenterol       Date:  2010-02-28       Impact factor: 5.742

Review 9.  Non-classical phenotypes of autoimmune hepatitis and advances in diagnosis and treatment.

Authors:  Albert J Czaja; Yusuf Bayraktar
Journal:  World J Gastroenterol       Date:  2009-05-21       Impact factor: 5.742

Review 10.  Drug therapy in the management of type 1 autoimmune hepatitis.

Authors:  A J Czaja
Journal:  Drugs       Date:  1999-01       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.